MK-906 (5MG) (50 TABLETS)

Type II 5α-Reductase Inhibitor | DHT Suppression, Scalp Hair Follicle Preservation & Prostate Care

Overview:
MK-906 (Finasteride) is a potent, competitive, and highly selective Type II 5α-reductase enzyme inhibitor. By blocking the peripheral enzymatic conversion of circulating testosterone into dihydrotestosterone (DHT), MK-906 reduces serum and tissue DHT concentrations by up to 60–70%. This rapid suppression prevents androgenic hair follicle miniaturization on the scalp and reduces prostate gland hypertrophy without decreasing circulating total testosterone levels.

This product is supplied as a secure bottle containing 50 oral tablets, with each tablet accurately dosed at 5mg of active Finasteride.

Exogenous androgen and testosterone protocols significantly elevate circulating DHT levels, accelerating androgenic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH) in genetically predisposed individuals. MK-906 targets the root cause of androgen-induced hair shedding by neutralizing Type II 5α-reductase activity in scalp tissue.

The 5mg tablet strength provides an economical high-potency formulation, easily split into custom daily micro-doses (such as 1.25mg or 2.5mg daily) or taken at full strength for maximum scalp and prostate protection across 50 tablets.

• Targeted Serum & Scalp DHT Reduction: Lowers circulating DHT levels by approximately 65–70% to arrest androgenic hair shedding.
• Reverses Follicle Miniaturization: Protects hair follicles on the crown and hairline from androgenic degradation.
• Prostate Tissue Protection: Prevents prostate hypertrophy and reduces baseline prostate-specific antigen (PSA) levels during heavy androgen runs.
• Preserves Free Testosterone: Blocks conversion pathways without binding to androgen receptors or suppressing endogenous gonadotropin signaling.
• Versatile 5mg Configuration: Allows for easy micro-splitting (1.25mg / 2.5mg) to manage individual protocol requirements.

• Half-Life & Timing: MK-906 has an active terminal elimination half-life of 6 to 8 hours, but tissue binding to the 5α-reductase enzyme persists for up to 24 hours. Taken once daily with water, with or without food.
• Protocol Timing: Consistently administer at the same time daily to maintain steady enzymatic inhibition and flat serum DHT curves.
• Swallowing: Swallow tablet (or split portion) whole with water. Do not crush or chew.

• Non-Steroidal: Does not act as an anabolic agent, estrogen modifier, or central gonadotropin suppressor.
• Libido & DHT Shifts: Significant reductions in systemic DHT may lead to transient decreases in libido or mild changes in erectile quality in sensitive users.
• PSA Interference: Lowers serum PSA concentrations by roughly 50%; account for this baseline drop when interpreting prostate health blood work.